Temgesic svälja
•
Temgesic Sublingual
Dosage and Titration: The lowest Temgesic Sublingual 5 mg should be used as the initial dose in all patients.
During initiation, titration, and treatment with Temgesic Sublingual, patients may continue their existing NSAID or acetaminophen regimen as needed.
The dose of Temgesic Sublingual should not be increased at less than 3-day intervals when steady-state levels are attained. Changes in Temgesic Sublingual dosage may be individually titrated based on the need for supplemental PRN analgesia and the patient's analgesic response to Temgesic Sublingual.
To increase the dose, a larger patch should replace the patch that is currently being worn, or a combination of patches should be applied in different places to achieve the desired dose. It is recommended that no more than two patches be applied at the same time, regardless of patch strength.
Titration should continue every days until adequate analgesia is achieved.
If adequate pain control cannot be achieved with Temgesic Sublingual, therapy should be discontinued and the patient converted to an appropriate analgesic regimen as determined by a physician.
Discontinuation: After removal of Temgesic S
•
Temgesic
Administration bygd the sublingual route.
Adults and children over 12:
tablets ( micrograms) to be dissolved beneath the tongue every hours or as required. The recommended starting dose for moderate to severe pain of the type typically presenting in general practice is 1 to 2 tablets, 8 hourly.
Elderly:
There is no evidence that dosage needs to be modified for the elderly.
Children under 12 years:
Temgesic Sublingual fryst vatten suitable for use in children beneath 12 as follows:
kg ( lb) ½ tablet
kg ( lb) ½ - 1 tablet
kg ( lb) ½ tablets
The recommended dose should be administered every hours.
Sublingual ledning is not suitable for children beneath the age of six years.
Temgesic sublingual may be used in balanced anaesthetic techniques at a dose of micrograms.
Special populations
Hepatic impairment
The effects of hepatic impairment on the pharmacokinetics of buprenorphine were evaluated in a postmarketing study. Buprenorphine is extensively metabolized in the liver, and plasma levels were found to be higher for buprenorphine in patients with moderate and severe hepatic impairment compared to healthy subjects. Patients should be monitored for
•
3 3
3 3
3
3
Pharmacode Reads This Way
PACKAGE LEAFLETT INFORMATION FORTHEUSEfi
Buprenorphine hydrochloride
||lNDIVIOR
Read all of this leaflet carefully before you start
taking this medicine.
- Keep this leaflet You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
~' In this leaflet:
! 1. What Temgesic Sublingual Tablets are and | what they are used for . 2. Before you take Temgesic Sublingual M Tablets
4 3. How to take Temgesic Sublingual Tablets ■4. Possible side effects □ 5. Howto store Temgesic Sublingual Tablets "l 6. Further information
1. WHATTEMGESIC SUBLINGUALTABLETS ARE ANDWHATTHEYARE USED FOR
Temgesic Sublingual Tablets are strong pain kille